1. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis 
Prof J Stuart Elborn, MD, Prof Bonnie W Ramsey, MD, Prof Michael P Boyle, MD, Michael W Konstan, MD, Xiaohong Huang, PhD, Gautham Marigowda, MD, David Waltz, MD, Prof Claire E Wainwright, MD 
The Lancet Respiratory Medicine 
Volume 4, Issue 8, Pages (August 2016)
DOI: /S (16)
Copyright © 2016 Elsevier Ltd Terms and Conditions

2. Figure 1
Absolute change from baseline in ppFEV1 at each study visit for patients with ppFEV1 levels lower than 40 (A) or 40 or higher (B) at baseline and lower than 70 (C) or 70 or higher (D) at screening
Error bars show 95% CI. ppFEV1=percent predicted FEV1.
The Lancet Respiratory Medicine 2016 4, DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

3. Figure 2
Percentage of patients with 5% or higher and 10% or higher average relative increases from baseline in ppFEV1 at weeks 16 and 24 in patients with ppFEV1 levels lower than 40 or 40 or higher at baseline (A) and ppFEV1 levels lower than 70 or 70 or higher at screening (B)
ppFEV1=percent predicted FEV1.
The Lancet Respiratory Medicine 2016 4, DOI: ( /S (16) )
Copyright © 2016 Elsevier Ltd Terms and Conditions